Effects of ONO-2506PO in Patients With Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Registration Number
- NCT00083421
- Lead Sponsor
- Ono Pharma USA Inc
- Brief Summary
The purpose of this study is to establish the presence of an effect of treatment with ONO-2506PO in patients with Alzheimer's Disease, based upon cognitive and global scales.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 647
- Diagnosis of probable Alzheimer's Disease using NINCDS/ADRDA criteria
- Standardized MMSE Score of 13 to 24 points (inclusive)
- Modified Hachinski score equal or less than 4
- Serious systemic disease that may preclude survival to study completion
- Other illnesses that may include dementive features
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Cognitive Function Scale Global Function Scale
- Secondary Outcome Measures
Name Time Method ADL Scale Psychiatric Symptom Scale
Trial Locations
- Locations (83)
Kirkland Clinic
🇺🇸Birmingham, Alabama, United States
Alzheimers Disease Research Center
🇺🇸Birmingham, Alabama, United States
Pivotal Research Center
🇺🇸Mesa, Arizona, United States
HOPE Research Institute
🇺🇸Phoenix, Arizona, United States
Sun Health Research Institute
🇺🇸Sun City, Arizona, United States
University of Arizona
🇺🇸Tucson, Arizona, United States
Margolin Brain Institute
🇺🇸Fresno, California, United States
UCI Medical Center Neuropsychiatric Center
🇺🇸Orange, California, United States
Pacific Neuroscience Medical Group
🇺🇸Santa Barbara, California, United States
The Southwest Institute for Clinical Research, Inc
🇺🇸Rancho Mirage, California, United States
Scroll for more (73 remaining)Kirkland Clinic🇺🇸Birmingham, Alabama, United States